Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis
The DOI matches its Crossref record.
Abstract
A high proportion of patients with cystic fibrosis (CF) develop diabetes mellitus. In common with type II diabetes mellitus, diabetes mellitus in CF is characterized by a progressive decline in beta-cell function and an approximately 50% decline in beta-cell mass. It is not known whether islet amyloidosis (characteristic of type II diabetes mellitus) is present in diabetes mellitus complicating CF. To address this, pancreatic samples were obtained at autopsy from 9 control cases (without CF) and 41 cases of CF that were, in turn, subdivided into 13 nondiabetic, 12 borderline diabetic, and 16 diabetic cases based on clinical criteria. Islet amyloid was detected by light microscopy in 69% cases of CF with diabetes mellitus, 17% of cases with borderline diabetes mellitus, and none of the nondiabetic cases. Islet amyloid was not present in any of the control cases. Islet amyloidosis derived from islet amyloid polypeptide is a characteristic feature of diabetes mellitus in CF as well as type II diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis
Haataja, L., Gurlo, T., Huang, C. J., & Butler, P. C. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0037 · Cited by 612
Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide.
Janson, J., Soeller, W. C., Roche, P. C., Nelson, R. T., Torchia, A. J., Kreutter, D. K., & Butler, P. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7283 · Cited by 342
Diagnosis, screening and management of cystic fibrosis related diabetes mellitus
Moran, A., Hardin, D., Rodman, D., Allen, H. F., Beall, R. J., Borowitz, D., Brunzell, C., Campbell III, P. W., Chesrown, S. E., Duchow, C., et al. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00058-3 · Cited by 293
Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes
Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee (2010) · Diabetes Care · doi:10.2337/dc10-1279 · Cited by 258
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171
Self-citationCystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al
Olesen, H. V., Drevinek, P., Gulmans, V. A., Hatziagorou, E., Jung, A., Mei-Zahav, M., Stojnic, N., Thomas, M., & Zolin, A. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.009 · Cited by 95
Ode, K. L., Ballman, M., Battezzati, A., Brennan, A., Chan, C. L., Hameed, S., Ismail, H. M., Kelly, A., Moran, A. M., Rabasa‐Lhoret, R., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13453 · Cited by 95
“26-28 Most PwCF, with or without CFRD, have lost about half of their islet mass. Data suggests β -cell loss is not simply a by-product of exocrine tissue damage but also a manifestation of reduced β -cell progenit or survival, β - cell proliferation, and perhaps β -cell specification of progenitors.”
BackgroundSelf-citationDiagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis
Siwamogsatham, O., Alvarez, J. A., & Tangpricha, V. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000096 · Cited by 36
Metadata
- Authors
- Couce, M.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1996-03-01
- Volume
- 81
- Issue
- 3
- Pages
- 1267-1272
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2039735560
- Cited by
- 126
- References
- 0
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.